AN2 Therapeutics (ANTX) Free Cash Flow (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Free Cash Flow data on file, last reported at -$12.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 13.9% year-over-year to -$12.1 million in Q1 2026; TTM through Mar 2026 was -$31.3 million, a 25.91% increase from a year earlier, with the FY2025 full-year figure at -$29.8 million, up 39.43% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$12.1 million, down from -$5.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for ANTX reached as high as -$5.2 million in Q4 2025 and fell as low as -$17.6 million in Q1 2024.
• Historically, Free Cash Flow has averaged -$10.5 million across 5 years, with a median of -$10.6 million in 2025.
• Across the five-year window, Free Cash Flow sank 336.94% in 2022 and soared 69.24% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$7.6 million in 2022, then plunged by 123.72% to -$17.1 million in 2023, then surged by 69.24% to -$5.3 million in 2024, then climbed by 0.4% to -$5.2 million in 2025, then sank by 130.58% to -$12.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$12.1 million in Q1 2026, -$5.2 million in Q4 2025, and -$6.4 million in Q3 2025.